MapLight Therapeutics, Inc. cotiza a 8.60 USD y tiene una capitalización bursátil de $478M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease p…
| Periodo | 2026-11 | 2026-08 | 2026-08 | 2026-05 |
|---|---|---|---|---|
| Real | — | $-1.32 | — | $-1.34 |
| Estimado | $-1.17 | $-1.31 | $-1.38 | $-1.09 |
| Sorpresa | — | -0.8% | — | -22.9% |
| Métrica | MPLT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -35.2% | -40.4% | +5.2% |
| ROA | -33.6% | -32.0% | -1.6% |
| Current Ratio | 20.01 | 2.84 | +17.17 |
| Debt / Equity | — | 0.28 | — |